XELJANZ/ XELJANZ XR May Cause Thrombosis
OTTAWA, Ontario, Canada — Health Canada, the governmental public health agency in Canada, announced a warning about the potential for Xeljanz/Xeljanz XR to cause thrombosis. Health Canada said that the agency is working closely with Pfizer Canada ULC with a plan to update the documentation that accompanies the drugs as well as issue … [Read more...] about XELJANZ/ XELJANZ XR May Cause Thrombosis
Xeljanz Blood Clots and Deaths: Black-Box Warning Issued
In July 2019, the U.S. Food and Drug Administration approved a black-box warning for the Xeljanz (tofacitinib) drug label due to a higher risk of blood clots and death. The changes followed a review of data from a clinical trial on the safety of Xeljanz and Xeljanz XR in patients with rheumatoid arthritis taking a higher daily dose … [Read more...] about Xeljanz Blood Clots and Deaths: Black-Box Warning Issued
Reports of Xeljanz and Xeljanz XR Blood Clot and Death Risks
FDA Approves New Black Box Warning for Xeljanz and Xeljanz XR Communicating Risk of Blood Clots and Death Xeljanz and Xeljanz XR are Janus Kinase Inhibitors (JAKs) and are part of the class of drugs called “disease-modifying antirheumatic drugs (DMARDs).” Xeljanz and Xeljanz XR are used to treat a variety of medical conditions, … [Read more...] about Reports of Xeljanz and Xeljanz XR Blood Clot and Death Risks
FDA Tofacitinib Warning Released Following Clinical Safety Study
On Friday, the U.S. Food and Drug Administration (FDA) released a drug information update and a drug safety communication concerning recent dangers found in the drug Xeljanz, known generically as tofacitinib. The FDA tofacitinib warning discussed new dangers and how healthcare providers and consumers can safeguard against … [Read more...] about FDA Tofacitinib Warning Released Following Clinical Safety Study
Fatalities Linked to Xeljanz and Jakafi
Thromboembolic Concerns Raised After Evidence Points to High Risk of Adverse Events Caused by Popular Drugs According to AJMC.com, one popular drug frequently prescribed to people suffering from rheumatoid arthritis and another that treats myelofibrosis and polycythemia vera has been linked to life-threatening thromboembolic … [Read more...] about Fatalities Linked to Xeljanz and Jakafi
Xeljanz and Jakafi Linked to Fatalities
Drug Defect Lawyers Parker Waichman LLP Discuss Janus Kinase Inhibitors’ Link to Serious Illness and Death According to AJMC.com, a review of the database repository maintained by the U.S. Food and Drug Administration to record adverse effects attributed to medications and other therapies, commonly referred to as FAERS, suggests … [Read more...] about Xeljanz and Jakafi Linked to Fatalities
